Avacta Therapeutics (AIM: AVCT) has reported strong progress across its oncology pipeline in the first half of 2026, highlighting advances in both its clinical programmes and balance sheet ahead of
£9m fundraising gives Avacta extra firepower for cancer pipeline
Avacta Therapeutics plc (AIM: AVCT) has strengthened its balance sheet after completing an oversubscribed £9 million equity fundraising, with proceeds earmarked primarily for reducing outstanding convertible bond debt and supporting
Avacta showcases progress in salivary gland cancer study
Avacta Group PLC (AIM: AVCT) unveiled encouraging new clinical data for its lead oncology candidate AVA6000 (faridoxorubicin) at the ASCO 2026 annual meeting, highlighting both promising efficacy and a potentially
Avacta Therapeutics (AIM: AVCT) Board Director Changes
Avacta Therapeutics (AIM: AVCT) has announced a boardroom transition, with Richard Hughes to be appointed non-executive chairman following the company’s Annual General Meeting on 22 June 2026.
Avacta strengthens cancer treatment story with clinical advances
Avacta Group plc has reported significant progress across its pre|CISION oncology platform in its unaudited preliminary results for the year ended December 31, 2025, as the company advances multiple cancer
Avacta Therapeutics (AIM: AVCT) Pre|CISION® payload release vs approved ADCs
Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
Avacta Therapeutics (AIM: AVCT) Avacta data AACR underline AVA6103 profile
Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform Presentation of additional analyses from FAP-Exd (AVA6103) study shows robust activity in PDX models with
Avacta Therapeutics (AIM: AVCT) Christina Coughlin – In Vivo 2026 Rising Leader
Avacta CEO Christina Coughlin Named as One of In Vivo’s 2026 Rising Leaders
Avacta Therapeutics (AIM: AVCT) Q1 2026 Business Update
LONDON and PHILADELPHIA – April 9, 2026 – Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today provides a business update through the first
Avacta Therapeutics (AIM: AVCT) Announces 2026 Science Day Event
LONDON and PHILADELPHIA – April 8, 2026 – Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to extend an open invitation for
Avacta Therapeutics (AIM: AVCT) First patient treated in Phase 1 trial of AVA6103
Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) – a sustained-release pre|CISION® exatecan peptide drug conjugate
Avacta raises £10m to fund next phase of cancer pipeline
Avacta Group has raised £10 million through an oversubscribed placing and subscription, issuing 15.87 million new shares at 63p, a discount of approximately 9.4% to the previous closing price.